Abstract
The patent and regulatory data protection periods for the first and second waves of biological agents based on recombinant proteins have started to expire, leaving open the potential for development and regulatory approval of 1 or more “similar” versions of these biologic therapies, termed biosimilars in Europe (BS)—the term that will be used in this chapter—subsequent entry biologics in Canada, or follow-on-biologics in the USA. The development of BS therapies could lead to a substantial saving for patients/health systems and, therefore, increased availability of effective treatments. BSs are similar but not identical to their reference products, because their chemical characteristics are directly related to the manufacturing process, which cannot be precisely duplicated. An exact replica of a protein molecule is extremely difficult if not impossible. Thus, major concerns about short- and long-term safety and efficacy have been raised and should be addressed in the approval process by regulatory agencies. For these reason, BSs require an approach to grant the marketing authorization, different from generics.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Abraham I, MacDonald K (2012) Clinical safety of biosimilar recombinant humanerythropoietins. Expert Opin Drug Saf 11:819–840
Bennett CL, Luminari S, Nissenson AR et al (2004) Pure red cell aplasia and epoetin therapy. N Engl J Med 351:1403–1408
Crommelin D, Bermejo T, Bissig M et al (2005) Biosimilars, generic versions of the first generation of therapeutic proteins: do they exist? Contrib Nephrol 149:287–294
Cuadrado MJ, Sciascia S, Bosch X, Khamashta MA, Ramos-Casals M (2013) Is it time for biosimilars in autoimmune diseases? Autoimmun Rev (March 28)
Dorner T, Strand V, Castaneda-Hernandez G et al (2013) The role of biosimilars in the treatment of rheumatic diseases. Ann Rheum Dis 72:322–328
Dranitsaris G, Amir E, Dorward K (2011) Biosimilars of biological drug therapies: regulatory, clinical and commercial considerations. Drugs 71:1527–1536
European Medicines Agency (2005) Guideline on similar biological medicinal products. http://www.emea.europa.eu/pdfs/human/biosimilar/043704en.pdf
FDA HR 3590-686 (2010) Administration UFaD. Patient Protection and Affordable Care Act. Title VII—Improving access to innovative medical therapies. Subtitle A Biologics price competition and innovation. Sec. 7002. Approval pathway for biosimilar biological products. US Department of Health & Human Services [online]. http://www.gpo.gov/fdsys/pkg/BILLS‑111hr3590eas/pdf/BILLS‑111hr3590eas.pdf
Franke LC, Ament AJ, van de Laar MA, Boonen A, Severens JL (2009) Cost-of-illness of rheumatoid arthritis and ankylosing spondylitis. Clin Exp Rheumatol 27(4 Suppl 55):S118–S123
Gershon SK, Luksenburg H, Cote’ TR et al (2002) Pure red cell aplasia and recombinant erythropoietin. N Engl J Med 346:1584–1585
Gu N, Yi S, Kim TE, Kim J, Shin SG, Jang IJ, Yu KS (2011) Comparative pharmacokinetics and tolerability of branded etanercept (25 mg) and its biosimilar (25 mg): a randomized, open-label, single-dose, two-sequence, crossover study in healthy Korean male volunteers. Clin Ther 33:2029–2037
Hughes DA (2010) Biosimilars: evidential standards for health technology assessment. Clin Pharmacol Ther 87:257–261
Huscher D, Merkesdal S, Thiele K, Zeidler H, Schneider M, Zink A (2006) Cost of illness in rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis and systemic lupus erythematosus in Germany. Ann Rheum Dis 65:1175–1183
Minghetti P, Rocco P, Del Vecchio L, Locatelli F (2011) Biosimilars and regulatory authorities. Nephron Clin Pract 117:c1–c7
Ramos-Casals M, Roberto-Perez-Alvarez, Diaz-Lagares C, Cuadrado MJ, Khamashta MA, BIOGEAS Study Group (2010) Autoimmune diseases induced by biological agents: a double-edged sword? Autoimmun Rev 9:188–193
Reichert JM, Beck A, Iyer H (2009) European Medicines Agency workshop on biosimilar monoclonal antibodies: July 2, 2009, London, UK. Landes Biosci mAbs 1:394–416
Schellekens H (2004) Biosimilar therapeutic agents: issues with bioequivalence and immunogenicity. Eur J Clin Invest 34:797–799
Schellekens H (2005) Immunologic mechanisms of EPO-associated pure red cell aplasia. Best Pract Res Clin Haematol 18:473–480
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2014 Springer Basel
About this chapter
Cite this chapter
Sciascia, S., Roccatello, D., Lopez-Pedrera, C., Cuadrado, M.J. (2014). The Future Potential of Biosimilars Targeting B-Cells. In: Bosch, X., Ramos-Casals, M., Khamashta, M. (eds) Drugs Targeting B-Cells in Autoimmune Diseases. Milestones in Drug Therapy. Springer, Basel. https://doi.org/10.1007/978-3-0348-0706-7_15
Download citation
DOI: https://doi.org/10.1007/978-3-0348-0706-7_15
Published:
Publisher Name: Springer, Basel
Print ISBN: 978-3-0348-0705-0
Online ISBN: 978-3-0348-0706-7
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)